Burning Rock Biotech (BNR) Capital Leases (2019 - 2020)

Burning Rock Biotech (BNR) posted quarterly Capital Leases of $116000.0 for Q3 2020, down 62.21% quarter-over-quarter from $307000.0 in Q2 2020.

Burning Rock Biotech (BNR) Capital Leases (2019 - 2020) Analysis & Trends

Burning Rock Biotech's Capital Leases history runs 2 years deep, the most recent figure standing at $116000.0 for Q3 2020.

In Q3 2020, Capital Leases changed N/A year-over-year to $116000.0; the TTM figure through Sep 2020 stood at $116000.0 (changed N/A YoY), while the FY2019 annual figure was $697491.0, changed N/A from the prior year.
Capital Leases for Q3 2020 stood at $116000.0, down from $307000.0 in the prior quarter.
The five-year high for Capital Leases was $683297.8 in Q4 2019, with the low at $116000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn
10	Burning Rock Biotech	781.17 Mn	711.04 Mn	11.31 Mn

Download Data